Study Group: Experts on Generic Pharmaceuticals: Pharmacists
Council Members in this Study Group: 106
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Bruce Goldberg
President
Pharmacy Benefit Advisors
Bruce Goldberg is the President of Pharmacy Express Services and Pharmacy Benefit Advisors, both based in Omaha, Nebraska. He is a pharmacist and has experience in managed care with PBM contracting and general pharmacy network management. He developed...
- Leo Pavliv
VP Operations
CUMBERLAND PHARMACEUTICALS, INC.Leo Pavliv, RPh, MBA, is Vice President Operations at Cumberland Pharmaceuticals in Tennessee. His job responsibilities include directing overall drug development activities for numerous products, regulatory affairs, product development, clinical and...
David ZimmermanPresident/Owner
Doctors of Pharmacy, Inc.David Zimmerman, PharmD, FASCP, is the President and an Independent Consultant of Doctors of Pharmacy. Dr. Zimmerman formerly served as the Director of Clinical Affairs at Employee Health Insurance Management, a pharmacy benefit manager. He has over 30...
Steven MillerPresident
Steven Miller, MS, DPHSteven Miller, MSPharm, DPH, is the President and Chief Executive Officer of SJM Enterprises, a multi-faceted consumer-response organization, specializing in workers compensation, medication therapy management, and managed care pharmaceutical reimbursement...
Dea BelaziPharmacy Consultant
Dea Belazi, PharmD, MPH, PAHMDea Belazi, PharmD, MPH, PAHM, is currently a Consultant working with health plans and pharmaceutical companies. Dr. Belazi is also a Consulting Practice Leader for Wolters Kluwer Health- Managed Care Group. Previously, he was the Senior Director of Pharmacy...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Thriving in a time of adversity - Sun Pharma pounces on shortage by getting approval on Oxycodone
April 13, 2009
Analysis by: Aemad Aslam, President,Sun Pharma gets USFDA's nod to market painkillers | www.hindu.com
Sun Pharma can greatly benefit from the nationwide shortage of Oxycodone Immediate Release Tablet, by getting approval from the FDA on their own generic. With recent recalls from different manufacturers, and the shortage of a comparable product Morphine Sulphate, the FDA currently estimates that return to normal supply levels of Oxycodone may occur in approximately 2 months, during which time Sun Pharma can capitalize on the shortage by securing longer term contracts with wholesalers.
-
Aurobindo Pharma's Escitalopram will be a big mover ... when it comes out in 2011
March 5, 2009
Analysis by: Aemad Aslam, President,Aurobindo Pharma receives tentative approval for Escitalopram | www.indiainfoline.com
Forest's Lexapro commands a $2.5+ billion USD market share, just in the US. Due to such a high volume of the brand product, Aurobindo's tentative approval on Lexapro's generic Escitalopram will be a great opportunity - primarily if they can procure a 6 month period of exclusivity from the FDA. Additionally, despite being a brand name product, Lexapro holds an 8%+ year over year increase in the past 3 years. Hence, the market for the drug in September of 2011 when the patent runs out will be closer to a $3 billion market.
-
Teva's Generic Imitrex commands market of Sumatriptan
February 26, 2009
Analysis by: Aemad Aslam, President,Teva Announces Approval and Launch of Generic Imitrex(R) Tablets | www.pipelinereview.com
With the 180 day exclusivity, Teva is already commanding the market of the generic Imitrex - Sumatriptan oral tablets. Teva maintains an AB rating of the generic that will render most insurance companies to push brand name Imitrex by GlaxoSmithKline to a non-formulary tier, skyrocketing the generic's sales. Already, different wholesalers are reporting a backorder on Teva's generics. Additionally, Teva's pricing point is very favorable to itself, despite Dr Reddy's prior entrance.
-
Acquisitions of Indian Pharma on the extended horizon by Brand name pharma
February 23, 2009
Analysis by: Aemad Aslam, President,Pharma cos on lookout for Indian drug firms | economictimes.indiatimes.com
Acquisitions of various Indian generic pharmaceuticals is likely on the horizon for brand name manufacturers. However, this is not an immediate concern. I would see more consolidations in the US and other Western markets first.
-
Sun Pharma - much stronger with acquisitions including Taro
February 17, 2009
Analysis by: Aemad Aslam, President,As valuations dip, Sun Pharma is in M&A mode | economictimes.indiatimes.com
Sun Pharma is attempting to gain market share in the world largest market - the US market. Sun Pharma is clearly expanding it product base with venturing into topical (dermatological) and pediatric segments, and with vertical integration as with raw materials suppliers. Sequentially, I would see SunPharma to be a leader in the US market within this decade, unless other Indian manufacturers encroach in this market.
Members in this Study Group include these company types:
- Pharmacy or Drug Store, Chain
- Pharmacy or Drug Store, Independent/Local
- Consultancy, Pharma-Focused
- Facility, Academic Medical Center
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Pharmaceuticals Manufacturer
Members in this Study Group often have these job titles:
- Director
- Pharmacist - RPh/PharmD
- Owner
- Manager
- President
- Operations Executive
- Consultant
- Principal
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 766 |
| Pharmacists (US) | 2077 |
| Formulary Design Experts | 250 |
| Economic Experts on Formulary Designs (US) | 51 |
| Economic Experts on Managed Care | 714 |
| Zocor Pricing Experts (US) | 38 |
| Medicare Experts | 493 |
| Pharmacists at Hospitals | 634 |
GLG Live Meetings with this Study Group's Leading Experts (?)
July 31, 2007 | Boston
GLGi: Managed Care FormularyJuly 30, 2007 | New York
GLGi: Managed Care FormularyGLG Webcasts & Teleconferences
Leading Experts in Experts on Generic Pharmaceuticals: Pharmacists have not participated in any GLG webcasts.